Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Saudi Arabia's Pharma Market Is 'Open For Business'

This article was originally published in Scrip

Executive Summary

Saudi Arabia could be an exciting market for many pharmaceutical companies looking to grow their business. Not only is it the biggest market in the Gulf, worth $5.1bn in 2012, but it is also an important gateway for other markets in a region where demand is steadily growing. And now new developments at the Saudi Food & Drugs Authority (SFDA) means that firms will likely find it easier to get to the market, explains Hassaan Alwohaibi, director of product licensing at the SFDA's drug division.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064930

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel